main content start
Synjardy and Synjardy XR combines empagliflozin and metformin. Empagliflozin lowers blood glucose (or blood sugar) levels by excreting glucose through the urine. Metformin decreases the glucose production excreted from the liver. Metformin in Synjardy XR is extended release.
The empagliflozin in Synjardy has been shown to reduce the risk of death from heart disease and the risk of kidney failure.
Synjardy is approved for adults and children (10 years and older) with type 2 diabetes. Synjardy XR is approved for adults with type 2 diabetes.
- Synjardy is approved for adults and children 10 years and older with type 2 diabetes. Synjardy XR is approved for adults with type 2 diabetes. It is not for treating type 1 diabetes.
- For adults with type 2 diabetes and heart disease, the empagliflozin in Synjardy is also used to lower the risk of death from heart attack, stroke, or heart failure.
- For adults with type 2 diabetes and chronic kidney disease, Synjardy is also used to lower the risk of kidney failure.
- Synjardy is a tablet taken with food.
- Common side effects may include GI intolerance, increased urinary frequency, dizziness, and genital-urinary infections.
Synjardy and Synjardy XR Specs
Key specification
Generic Name
Empagliflozin and Metformin Empagliflozin and Metformin HCl (Synjardy XR)
Approved for Kids
10+ with type 2 diabetes (Synjardy)
Drug Class
SGLT-2 inhibitors
General Information
Product Name
Synjardy and Synjardy XR
Product Type
Oral Medications
Brand
BOEHRINGER INGELHEIM
Other Devices & Supplies
Looking for a different way to manage diabetes care? Browse and compare information on the latest devices, tools, and technology.
